More Veritas In Silico Inc. news
Veritas In Silico Inc.TSE: 130A

Completion of Pre-development Consultation with PMDA and Future Prospects for Proprietary Drug Delivery System "Perfusio(R)"

Nov 11, 2026 at 1:30 AM EST · Issued by Veritas In Silico Inc. via TDnet

Filed with TSE · Nov 11, 2026 at 1:30 AM EST · 3 pages · English

On 6ix: 6ix.com/news/completion-of-pre-development-consultation-with-pmda-and-future-prospects-for-proprietary-drug-delivery-system-perfusior

Veritas In Silico Inc. on 6ix

In the deck

  • Veritas In Silico — Q3 2026 Earnings Presentation21 slidesNov 11, 2026

Earlier from Veritas In Silico

  • Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment OptioNov 2
  • Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted CompoundsNov 2
  • Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party AllotmentOct 29
  • Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.Oct 19
  • Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]Aug 5

Later from Veritas In Silico

  • Announcement of Patent Grant for a Novel Nucleic Acid Therapeutic for Amyotrophic Lateral Sclerosis (ALS)Nov 16
All Veritas In Silico news releases↗

Follow Veritas In Silico into a list and get an email when it puts out news.

Follow Veritas In Silico
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer